Eton Pharmaceuticals, Inc. is rated Buy with revenue growth, FCF positivity & declining SG&A margins support. Learn more ...

The VanEck Pharmaceutical ETF (NYSEARCA:PPH) has surged 26% over the past year, driven almost entirely by the weight-loss ...

Global pharmaceutical production surged in 2025 due to tariff-driven front-loading but is expected to slow as trade ...

While the threat of U.S. import tariffs prompted a surge in drug production last year, that output is slated to slow across multiple geographies in 2026. | While the threat of U.S. import tariffs ...

CDMOs are expanding to provide integrated services, enhancing outsourcing appeal. Sustainability mandates boost adoption of advanced systems, and growth is pronounced in excipient innovation and ...

Danish dermatology specialist Leo Pharma and its CEO Christophe Bourdon came to San Francisco to attend the J.P. Morgan ...

Bayer AG’s pharmaceuticals unit is on track for a return to growth as new drugs for cancer and kidney disease offset sales ...

Life sciences mergers and acquisitions surged back in force in 2025, as pharmaceutical and med-tech companies moved ...

SpyGlass Pharma is pursuing a $100 million IPO to advance its glaucoma drug delivery platform through Phase 3 trials. Read ...

By Patricia Weiss BERLIN, Jan 13 (Reuters) - The pharmaceuticals and agriculture group Bayer aims to return its ...

Royalty Pharma reports Q1 2025 financials with 17% portfolio receipts growth, raising 2025 guidance to $2,975-$3,125 million. Royalty Pharma plc announced its financial results for the first quarter ...

Telix Pharmaceuticals meets its FY25 revenue target with strong Q4 growth, expanded U.S. launches and ongoing trials.